CareDx Q2 Revenue Surges 52% to $132M, Raises 2026 Guidance

summarizeSummary

CareDx reported Q2 revenue of $132 million, up 52% year-over-year, and raised its full-year 2026 revenue and adjusted EBITDA guidance. The quarter included a $113 million gain from the sale of its lab products business and the closing of the Naveris acquisition.

check_boxKey Events · Earnings and Guidance · CDNA

• Q2 Revenue +52% to $132M

  Total revenue reached $132 million, driven by a 61% increase in Testing Services to $100 million. Testing volume grew 17% to approximately 58,000 tests.

• GAAP Net Income of $111M

  GAAP net income was $111 million, or $2.07 per diluted share, including a $113 million gain on the sale of the lab products business. Non-GAAP net income was $20 million, or $0.37 per diluted share.

• Adjusted EBITDA of $25M

  Adjusted EBITDA rose to $25 million from $5 million a year ago, reflecting strong revenue growth and operating leverage.

• Raised 2026 Guidance

  Full-year revenue guidance raised to $490–$500 million (from $447–$465 million) and adjusted EBITDA guidance raised to $66–$78 million (from $43–$57 million).

auto_awesomeAnalysis · CDNA · Industrial Applications And Services

A standout quarter for CareDx was fueled by a 61% jump in Testing Services, propelling overall revenue growth of 52%. Confidence in sustained momentum is evident as the company raised its full-year revenue and adjusted EBITDA guidance well above prior ranges. The period also featured a $113 million gain from the lab products divestiture, which closed on June 30, and the completion of the Naveris acquisition, reshaping the business around high-growth transplant diagnostics and oncology. With $374 million in cash and positive operating cash flow, the balance sheet is strong. The stock is trading near its 52-week high, reflecting the market's positive reception to the strategic transformation and improving fundamentals.